The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Varicella Attenuated Live Vaccine Market Research Report 2024
Synopsis
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccine market was valued at US$ 2553.6 million in 2023 and is anticipated to reach US$ 3440.8 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.
Report Scope
The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Varicella Attenuated Live Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Varicella Attenuated Live Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Varicella Attenuated Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccine market was valued at US$ 2553.6 million in 2023 and is anticipated to reach US$ 3440.8 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.
Report Scope
The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Varicella Attenuated Live Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Varicella Attenuated Live Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Varicella Attenuated Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Varicella Attenuated Live Vaccine Market Overview
1.1 Product Overview and Scope of Varicella Attenuated Live Vaccine
1.2 Varicella Attenuated Live Vaccine Segment by Type
1.2.1 Global Varicella Attenuated Live Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine Segment by Application
1.3.1 Global Varicella Attenuated Live Vaccine Market Value by Application: (2024-2030)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Attenuated Live Vaccine Market Size Estimates and Forecasts
1.4.1 Global Varicella Attenuated Live Vaccine Revenue 2019-2030
1.4.2 Global Varicella Attenuated Live Vaccine Sales 2019-2030
1.4.3 Global Varicella Attenuated Live Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Varicella Attenuated Live Vaccine Market Competition by Manufacturers
2.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Varicella Attenuated Live Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Varicella Attenuated Live Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
2.7 Varicella Attenuated Live Vaccine Market Competitive Situation and Trends
2.7.1 Varicella Attenuated Live Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Varicella Attenuated Live Vaccine Players Market Share by Revenue
2.7.3 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Varicella Attenuated Live Vaccine Retrospective Market Scenario by Region
3.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Varicella Attenuated Live Vaccine Global Varicella Attenuated Live Vaccine Sales by Region: 2019-2030
3.2.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2019-2024
3.2.2 Global Varicella Attenuated Live Vaccine Sales by Region: 2025-2030
3.3 Global Varicella Attenuated Live Vaccine Global Varicella Attenuated Live Vaccine Revenue by Region: 2019-2030
3.3.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2019-2024
3.3.2 Global Varicella Attenuated Live Vaccine Revenue by Region: 2025-2030
3.4 North America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.4.1 North America Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.4.3 North America Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.5.1 Europe Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.5.3 Europe Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.7.1 Latin America Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Varicella Attenuated Live Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Varicella Attenuated Live Vaccine Sales by Type (2019-2030)
4.1.1 Global Varicella Attenuated Live Vaccine Sales by Type (2019-2024)
4.1.2 Global Varicella Attenuated Live Vaccine Sales by Type (2025-2030)
4.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2019-2030)
4.2.1 Global Varicella Attenuated Live Vaccine Revenue by Type (2019-2024)
4.2.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2025-2030)
4.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Varicella Attenuated Live Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Varicella Attenuated Live Vaccine Sales by Application (2019-2030)
5.1.1 Global Varicella Attenuated Live Vaccine Sales by Application (2019-2024)
5.1.2 Global Varicella Attenuated Live Vaccine Sales by Application (2025-2030)
5.1.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2019-2030)
5.2.1 Global Varicella Attenuated Live Vaccine Revenue by Application (2019-2024)
5.2.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2025-2030)
5.2.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Varicella Attenuated Live Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 BCHT
6.2.1 BCHT Corporation Information
6.2.2 BCHT Description and Business Overview
6.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
6.2.5 BCHT Recent Developments/Updates
6.3 Shanghai Institute
6.3.1 Shanghai Institute Corporation Information
6.3.2 Shanghai Institute Description and Business Overview
6.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
6.3.5 Shanghai Institute Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Keygen
6.5.1 Keygen Corporation Information
6.5.2 Keygen Description and Business Overview
6.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
6.5.5 Keygen Recent Developments/Updates
6.6 Green Cross
6.6.1 Green Cross Corporation Information
6.6.2 Green Cross Description and Business Overview
6.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
6.6.5 Green Cross Recent Developments/Updates
6.7 Biken
6.6.1 Biken Corporation Information
6.6.2 Biken Description and Business Overview
6.6.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
6.7.5 Biken Recent Developments/Updates
6.8 Shanghai Rongsheng Biotech
6.8.1 Shanghai Rongsheng Biotech Corporation Information
6.8.2 Shanghai Rongsheng Biotech Description and Business Overview
6.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
6.8.5 Shanghai Rongsheng Biotech Recent Developments/Updates
6.9 Changchun Changsheng Life Sciences Limited
6.9.1 Changchun Changsheng Life Sciences Limited Corporation Information
6.9.2 Changchun Changsheng Life Sciences Limited Description and Business Overview
6.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
6.9.5 Changchun Changsheng Life Sciences Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Varicella Attenuated Live Vaccine Industry Chain Analysis
7.2 Varicella Attenuated Live Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Varicella Attenuated Live Vaccine Production Mode & Process
7.4 Varicella Attenuated Live Vaccine Sales and Marketing
7.4.1 Varicella Attenuated Live Vaccine Sales Channels
7.4.2 Varicella Attenuated Live Vaccine Distributors
7.5 Varicella Attenuated Live Vaccine Customers
8 Varicella Attenuated Live Vaccine Market Dynamics
8.1 Varicella Attenuated Live Vaccine Industry Trends
8.2 Varicella Attenuated Live Vaccine Market Drivers
8.3 Varicella Attenuated Live Vaccine Market Challenges
8.4 Varicella Attenuated Live Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
